Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2025

Stockholders' Equity Note [Abstract]

The following table presents the Company’s authorized, issued, and outstanding common stock as of the dates indicated:


	Authorized	Issued	Outstanding
Common stock as of December 31, 2025
Class A	10,500,000,000	49,694,610	46,791,082
Class B	4,500,000,000	8,985,839	8,416,216
Class C	800,000,000	3,000,000	3,000,000
	15,800,000,000	61,680,449	58,207,298
Common stock as of December 31, 2024
Class A	10,500,000,000	45,575,423	42,696,585
Class B	4,500,000,000	9,239,682	8,669,200
Class C	800,000,000	3,000,000	3,000,000
	15,800,000,000	57,815,105	54,365,785

Schedule of Common Stock Reserved For Future Issuances

The Company had the following common stock reserved for future issuance as of the date indicated:


			December 31, 2025
Shares available for grant under the 2021 Plan			3,336,606
Restricted stock units outstanding			1,262,853
Performance stock units outstanding			4,407,287
Warrants to purchase Class A common stock			1,295,622
Shares available for grant under the ESPP			2,500,000
Shares available for grant under the 2022 Inducement Plan			292,172
Stock options issued and outstanding			366,567
Total common stock reserved for future issuances (1)			13,461,107

(1)Excludes unvested earnout shares, which are restricted shares issued to equity holders of legacy Ginkgo prior to the closing of the SRNG Business Combination and to SRNG. These earnout shares are recorded in equity as shares outstanding upon satisfying the vesting conditions.

Ginkgo Bioworks Holdings, Inc. 10-K